[Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
Kishimoto
Hideaki
H
Department of Orthopedic Surgery, San-in Rosai Hospital.
D019386:Alendronate / Q000008:administration & dosage* / Q000009:adverse effects; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016723:Bone Remodeling; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D012968:Etidronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D008159:Lumbar Vertebrae / Q000378:metabolism; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D010349:Patient Compliance; D000068296:Risedronic Acid; D016103:Spinal Fractures / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control
D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate